PRESSRELEASE

SHIONOGI

Shionogi Europe turns Paddington headquarters blue for World AMR Awareness Week 2025

- **Celebrating the birthplace of antibiotics and raising awareness of the urgent global threat of antimicrobial resistance (AMR)**

London, 18 November 2025 — Shionogi Europe, a leading pharmaceutical company specialising in developing medicines for infectious diseases, illuminated its London offices in Paddington blue today, to mark World Antimicrobial Awareness Week (WAAW). WAAW is a World Health Organisation (WHO) initiative, which aims to draw attention to the urgent, global health threat of antimicrobial resistance (AMR). AMR happens when harmful microbes, like bacteria, viruses and fungi, stop responding to the drugs developed to treat the common infections they cause.

According to the WHO, one in six bacterial infections worldwide are now resistant to current antibiotic treatments[1]. AMR is directly responsible for over one million deaths and contributes to almost five million deaths globally every year.[2] This figure is set to rise to over eight million people globally who will die each year from causes associated with AMR by 2050.[2]

Shionogi's offices will be lit blue all week – the official colour of World AMR Awareness Week – to symbolise the company's ongoing commitment to combating antimicrobial resistance and promoting public understanding of this growing global health challenge.

"Paddington is the birthplace of antibiotics. We have been fortunate to have had effective medicines to treat common infections ever since Alexander Fleming discovered penicillin in his lab at St Mary's Hospital, right here in Paddington, only 100 years ago. This revolutionised medicine, saving millions of lives, but antimicrobial resistance is now a very serious global health threat that affects us all", said Huw Tippett, CEO at Shionogi Europe.

"We're determined to keep using our scientific expertise to find new treatments that will help us stay one step ahead of the 'superbugs' that could potentially lead to a future where cancer therapy, routine surgeries like caesarean sections and hip replacements, and event common dental treatments, become too risky because of the threat of untreatable infection. By turning our Paddington headquarters blue this week, we hope to spark conversations that help raise awareness and encourage responsible use of

antibiotics. Together, we can safeguard the future of antibiotics and ensure that life-saving treatments remain effective for generations to come" Tippett explained.

In recent years, the number of companies involved in the research and development of much needed new treatments has drastically declined. According to the WHO, the number of antibacterials in the clinical pipeline decreased from 97 in 2023 to 90 in 2025 and only 5 of these are effective against at least one of the WHO list of "critical" bacteria.[3]

Shionogi Europe invites healthcare professionals, policy makers, patients, and the public to join in the global effort to address AMR. The company will be taking part in educational events, sharing resources, and supporting local and international partnerships working to tackle AMR throughout the week.

For further information please contact:
pressoffice@shionogi.eu

About Shionogi Europe
Shionogi B.V. (known as "Shionogi Europe") is the European headquarters of Shionogi & Co., Ltd, a leading global research-driven pharmaceutical company based in Osaka, Japan. Shionogi has a strong heritage in the field of anti-infectives, with a strong track record in discovering and developing novel medicines for antimicrobial resistance (AMR), HIV and influenza, and has been developing antimicrobial therapies for more than 60 years. Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on R&D in anti-infectives. For more information about Shionogi Europe's work in infectious diseases and its commitment to AMR awareness, please visit https://www.shionogi.com/eu/en/sustainability/sustainability.html.

About Antimicrobial Resistance (AMR)
Antimicrobials – including antibiotics, antivirals, antifungals, and antiparasitics – are medicines used to prevent and treat infectious diseases in humans, animals and plants. Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become difficult or impossible to treat, increasing the risk of disease spread, severe illness, disability and death. AMR is a natural process that happens over time through genetic changes in pathogens. Its emergence and spread is accelerated by human activity, mainly the misuse and overuse of antimicrobials to treat, prevent or control infections in humans, animals and plants.[4]

About World Antimicrobial Resistance Awareness Week (WAAW)
WAAW takes place from 18 to 24 November each year and is led globally by the World Health Organization (WHO). It aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of drug-resistant infections. European Antibiotic Awareness Day (EAAD), led by the European Centre for Disease Control (ECDC) is a public health initiative aimed at encouraging responsible use of antibiotics. It is held on 18 November every year.

References:

1. Global antibiotic resistance surveillance report 2025, accessed November 2025
2. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 The Lancet, 2024
3. WHO releases new reports on new tests and treatments in development for bacterial infections, accessed November 2025
4. Antimicrobial resistance factsheet. WHO. Accessed November 2025

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.